Senior clinical research scientist at Acumen Pharmaceuticals.
Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD
November 1st 2024The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]